15.03.2012 • News

Colin Minchom Appointed VP Particle Design BU at Hovione

Hovione said it has appointed Dr. Colin Minchom as vice president of its Particle Design business unit. Dr. Minchom was most recently with Patheon where he held the position of vice president, Pharmaceutical Development Services for North America. Based in East Windsor, NJ, Dr. Minchom will report to Hovione CEO Guy Villax.

Dr. Minchom's 29-year career includes extensive experience in the process, science and global regulation of drug development with emphasis on dosage forms and drug delivery. Prior to this role at Patheon, Dr. Minchom was head of Pharmaceutical Sciences at Cerebrus, a UK privately held pharmaceutical company and has also held positions of increasing scientific and management responsibility at Eli Lilly and E.R. Squibb in formulation and product development, project management and product management.

 

 

Company

Hovione

Sete Casas
2674-506 Loures
Portugal

Company contact







Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.